Single User License
INR 340509
Site License
INR 681018
Corporate User License
INR 1021527

Service Tax Additional

select a format
Price

Single User License
USD 4995
Site License
USD 9990
Corporate User License
USD 14985

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Glaucoma-Japan Drug Forecast and Market Analysis to 2023

Glaucoma-Japan Drug Forecast and Market Analysis to 2023


  Request for Sample Report

Executive Summary

Glaucoma-Japan Drug Forecast and Market Analysis to 2023

Summary

Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market. The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aerie's Rhopressa, Bausch & Lomb's Vesneo (latanoprost bunod), and Inotek's trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market.

GlobalData estimates that drug sales for glaucoma in Japan during 2013 reached USD 449m, making this the second largest market within the 7MM. GlobalData estimates that the glaucoma market will follow a steady growth trend throughout the forecast period. In part, this can be attributed to the introduction of three new products between 2013 and 2023 that will become a source for positive growth.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of Glaucoma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Japan from 2013-2023.

Analysis of the impact of key events as well the drivers and restraints affecting Japan Glaucoma market.

Reasons To Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Glaucoma.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2013-2023 in Japan.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Introduction 10

2.1 Catalyst 10

2.2 Related Reports 10

3 Disease Overview 12

3.1 Etiology and Pathophysiology 14

3.1.1 Etiology 14

3.1.2 Pathophysiology 17

3.2 Classification 20

3.3 Symptoms 21

3.4 Diagnosis 22

4 Disease Management 27

4.1 Diagnosis and Treatment Overview 27

4.1.1 Diagnosis 27

4.1.2 Treatment Guidelines 28

4.1.3 Leading Prescribed Drugs 30

4.1.4 Clinical Practice 30

4.2 Japan 32

5 Competitive Assessment 37

5.1 Overview 37

5.2 Product Profiles-Main Brands and Drug Classes 39

5.2.1 Xalatan (latanoprost) 39

5.2.2 Lumigan (bimatoprost) 45

5.2.3 Travatan (travoprost) 49

5.2.4 Tapros (tafluprost) 53

5.2.5 Beta Blockers 60

5.2.6 Carbonic Anhydrase Inhibitors 65

5.2.7 Alpha-Adrenergic Agonists 69

5.2.8 Simbrinza (brinzolamide + brimonidine) 72

5.2.9 Glanatec (ripasudil hydrochloride hydrate) 75

6 Unmet Need and Opportunity 81

6.1 Overview 81

6.2 Simplified Dosing Regimen 85

6.2.1 Unmet Need 85

6.2.2 Gap Analysis 86

6.2.3 Opportunity 89

6.3 Reminder Systems 90

6.3.1 Unmet Need 90

6.3.2 Gap Analysis 90

6.3.3 Opportunity 91

6.4 Long-Acting Therapy 92

6.4.1 Unmet Need 92

6.4.2 Gap Analysis 93

6.4.3 Opportunity 94

6.5 New Classes of IOP-Lowering Drugs 96

6.5.1 Unmet Need 96

6.5.2 Gap Analysis 98

6.5.3 Opportunity 99

6.6 Neuroprotective Drugs 100

6.6.1 Unmet Need 100

6.6.2 Gap Analysis 102

6.6.3 Opportunity 104

6.7 Improved Diagnosis and Monitoring 105

6.7.1 Unmet Need 105

6.7.2 Gap Analysis 106

6.7.3 Opportunity 107

7 Pipeline Assessment 108

7.1 Overview 108

7.2 Clinical Trials 108

7.2.1 Clinical Trial Mapping 108

7.2.2 Clinical Trial Design 109

7.3 Promising Drugs in Clinical Development 110

7.3.1 Rhopressa 112

7.3.2 Roclatan 124

7.3.3 Vesneo 132

7.3.4 Bimatoprost SR 141

7.3.5 Trabodenoson 149

7.3.6 OPC-1085EL 157

7.3.7 DE-117 161

7.3.8 OXT-TP 164

7.4 Promising Drugs in Early-Stage Development 166

7.4.1 ROCK Inhibitor AMA-0076 166

7.4.2 Sustained-Release PGA Products 167

7.5 Other Drugs in Development 170

8 Market Outlook 171

8.1 Japan 171

8.1.1 Forecast 171

8.1.2 Key Events 175

8.1.3 Drivers and Barriers 176

9 Appendix 177

9.1 Bibliography 177

9.2 Abbreviations 218

9.3 Methodology 223

9.4 Forecasting Methodology 223

9.4.1 Percent Drug-Treated Patients 223

9.4.2 Drugs Included in Each Therapeutic Class 224

9.4.3 Launch and Patent Expiry Dates 225

9.4.4 General Pricing Assumptions 225

9.4.5 Individual Drug Assumptions 226

9.4.6 Pricing of Pipeline Agents 235

9.5 Primary Research-KOLs Interviewed for this Report 236

9.6 Primary Research-High-prescriber Survey 238

9.7 About the Authors 239

9.7.1 Analyst 239

9.7.2 Therapy Area Director 239

9.7.3 Epidemiologist 240

9.7.4 Global Head of Healthcare 240

9.8 About GlobalData 241

9.9 Disclaimer 241

1.2 List of Figures

Figure 1: Open and Closed Iridocorneal Angles 13

Figure 2: The Aqueous Humor Cycle 16

Figure 3: Optic Nerve Damage-Cupping 18

Figure 4: Comparison of Healthy and Glaucomous Optic Nerves 26

Figure 5: Glaucoma Clinical Treatment Flowchart 32

Figure 6: Glaucoma-Number of Phase II and III/IIb Clinical Trials in Various Drug Classes in the 7MM 109

Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in Glaucoma, 2013-2023 112

Figure 8: Rhopressa's Development in Glaucoma 120

Figure 9: Clinical and Commercial Positioning of Rhopressa 122

Figure 10: Roclatan's Development in Glaucoma 129

Figure 11: Clinical and Commercial Positioning of Roclatan 130

Figure 12: Vesneo Development in Glaucoma 137

Figure 13: Clinical and Commercial Positioning of Vesneo 139

Figure 14: Clinical and Commercial Positioning of Bimatoprost SR 147

Figure 15: Trabodenoson's Development in Glaucoma 153

Figure 16: Clinical and Commercial Positioning of Trabodenosen 155

Figure 17: OPC-1085EL's Development in Glaucoma 159

Figure 18: Clinical and Commercial Positioning of OPC-1085EL 160

Figure 19: DE-117's Development in Glaucoma 163

Figure 20: Drug Sales by Class for Glaucoma in Japan, 2013-2023 174

1.1 List of Tables

Table 1: Symptoms of Glaucoma 22

Table 2: Diagnostic Tests for Glaucoma. 22

Table 3: National and International Treatment Guidelines for Glaucoma 29

Table 4: Most Prescribed Drugs for Glaucoma in the Global Markets, 2013 30

Table 5: Country Profile-Japan 36

Table 6: Leading Treatments for Glaucoma, 2013 38

Table 7: Product Profile-Xalatan 42

Table 8: Xalatan SWOT Analysis, 2014 43

Table 9: Global Sales Forecast (USD m) for Xalatan, 2013-2023 44

Table 10: Global Sales Forecast (USD m) for Generic Latanoprost, 2013-2023 44

Table 11: Product Profile-Lumigan 47

Table 12: Lumigan SWOT Analysis, 2014 48

Table 13: Global Sales Forecast (USD m) for Lumigan, 2013-2023 49

Table 14: Product Profile-Travatan 51

Table 15: Travatan SWOT Analysis, 2014 52

Table 16: Global Sales Forecast (USD m) for Travatan/Travatan Z, 2013-2023 53

Table 17: Global Overview of Tafluprost 53

Table 18: Product Profile-Tapros Franchise 56

Table 19: Tafluprost Adverse Events 58

Table 20: Tafluprost SWOT Analysis, 2014 58

Table 21: Global Sales Forecast (USD m) for the Tapros Franchise, 2013-2023 59

Table 22: Beta Blockers Available in the 7MM 62

Table 23: Global Sales Forecast (USD m) for Beta Blocker Drugs, 2013-2023 65

Table 24: Carbonic Anhydrase Inhibitors Available in the 7MM 66

Table 25: Global Sales Forecast (USD m) for Carbonic Anhydrase Inhibitor Drugs, 2013-2023 69

Table 26: Alpha-Adrenergic Agonists available in the 7MM 70

Table 27: Global Sales Forecast (USD m) for Alpha-Adrenergic Agonist Drugs, 2013-2023 72

Table 28: Product Profile-Simbrinza 73

Table 29: Simbrinza SWOT Analysis, 2014 74

Table 30: Global Sales Forecast (USD m) for Simbrinza, 2013-2023 75

Table 31: Product Profile-Glanatec 78

Table 32: Glanatec SWOT Analysis, 2014 80

Table 33: Global Sales Forecast (USD m) for Glanatec, 2013-2023 80

Table 34: Unmet Needs and Opportunities in Glaucoma 84

Table 35: Promising Drugs in Clinical Development for Glaucoma 110

Table 36: Comparison of Drugs in Development for Glaucoma, 2014 111

Table 37: Product Profile-Rhopressa 120

Table 38: SWOT Analysis-Rhopressa, 2014 123

Table 39: Global Sales Forecasts (USD m) for Rhopressa, 2013-2023 124

Table 40: Product Profile-Roclatan 128

Table 41: SWOT Analysis-Roclatan, 2014 131

Table 42: Global Sales Forecasts (USD m) for Roclatan, 2013-2023 132

Table 43: Product Profile-Vesneo 137

Table 44: SWOT Analysis-Vesneo, 2014 140

Table 45: Global Sales Forecasts (USD m) for Vesneo, 2013-2023 141

Table 46: Product Profile-Bimatoprost SR 146

Table 47: SWOT Analysis-Bimatoprost SR, 2014 148

Table 48: Global Sales Forecasts (USD m) for Bimatoprost SR, 2013-2023 149

Table 49: Product Profile-Trabodenosen 153

Table 50: SWOT Analysis-Trabodenoson, 2014 156

Table 51: Global Sales Forecasts (USD m) for Trabodenosen, 2013-2023 157

Table 52: Product Profile-OPC-1085EL 158

Table 53: SWOT Analysis-OPC-1085EL, 2014 160

Table 54: Global Sales Forecasts (USD m) for OPC-1085EL, 2013-2023 161

Table 55: Product Profile-DE-117 163

Table 56: SWOT Analysis-DE-117, 2014 164

Table 57: Product Profile-OXT-TP 165

Table 58: SWOT Analysis-OTX-TP, 2014 166

Table 59: Drugs in Development, 2014 170

Table 60: Japan Sales Forecast (USD m) for Glaucoma, 2013-2023 173

Table 61: Key Events Impacting Sales for Glaucoma in Japan, 2013-2023 175

Table 62: Glaucoma Market-Drivers and Barriers in Japan, 2013-2023 176

Table 63: Key Launch Dates 225

Table 64: Key Patent Expiries 225

Table 65: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 238

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com